Standard
Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL. / Husby, Simon; Bæch-Laursen, Cecilie; Eskelund, Christian W.; Favero, Francesco; Jespersen, Jakob Schmidt; Hutchings, Martin; Pedersen, Lone Bredo; Niemann, Carsten U.; Weischenfeldt, Joachim; Räty, Riikka; Larsen, Thomas Stauffer; Kolstad, Arne; Jerkeman, Mats; Grønbæk, Kirsten.
In:
Leukemia, Vol. 36, 2022, p. 2912-2916.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Husby, S, Bæch-Laursen, C, Eskelund, CW
, Favero, F, Jespersen, JS, Hutchings, M, Pedersen, LB
, Niemann, CU, Weischenfeldt, J, Räty, R, Larsen, TS, Kolstad, A, Jerkeman, M
& Grønbæk, K 2022, '
Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL',
Leukemia, vol. 36, pp. 2912-2916.
https://doi.org/10.1038/s41375-022-01725-8
APA
Husby, S., Bæch-Laursen, C., Eskelund, C. W.
, Favero, F., Jespersen, J. S., Hutchings, M., Pedersen, L. B.
, Niemann, C. U., Weischenfeldt, J., Räty, R., Larsen, T. S., Kolstad, A., Jerkeman, M.
, & Grønbæk, K. (2022).
Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL.
Leukemia,
36, 2912-2916.
https://doi.org/10.1038/s41375-022-01725-8
Vancouver
Husby S, Bæch-Laursen C, Eskelund CW
, Favero F, Jespersen JS, Hutchings M et al.
Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL.
Leukemia. 2022;36:2912-2916.
https://doi.org/10.1038/s41375-022-01725-8
Author
Husby, Simon ; Bæch-Laursen, Cecilie ; Eskelund, Christian W. ; Favero, Francesco ; Jespersen, Jakob Schmidt ; Hutchings, Martin ; Pedersen, Lone Bredo ; Niemann, Carsten U. ; Weischenfeldt, Joachim ; Räty, Riikka ; Larsen, Thomas Stauffer ; Kolstad, Arne ; Jerkeman, Mats ; Grønbæk, Kirsten. / Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL. In: Leukemia. 2022 ; Vol. 36. pp. 2912-2916.
Bibtex
@article{26f71fe7c9f546e4a2ef5bd4d9e53baa,
title = "Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL",
author = "Simon Husby and Cecilie B{\ae}ch-Laursen and Eskelund, {Christian W.} and Francesco Favero and Jespersen, {Jakob Schmidt} and Martin Hutchings and Pedersen, {Lone Bredo} and Niemann, {Carsten U.} and Joachim Weischenfeldt and Riikka R{\"a}ty and Larsen, {Thomas Stauffer} and Arne Kolstad and Mats Jerkeman and Kirsten Gr{\o}nb{\ae}k",
note = "Funding Information: The research was supported by Rigshospitalets Research Foundation and the Novo Nordisk Foundation (Novo Nordisk Foundation Center for Stem Cell Biology, DanStem; grant NNF17CC0027852). The project is part of the Danish Research Center for Precision Medicine in Blood Cancers funded by the Danish Cancer Society grant no. R223-A13071 and Greater Copenhagen Health Science Partners. The clinical trial was investigator-initiated and supported by Janssen and Celgene. ",
year = "2022",
doi = "10.1038/s41375-022-01725-8",
language = "English",
volume = "36",
pages = "2912--2916",
journal = "Leukemia",
issn = "0887-6924",
publisher = "nature publishing group",
}
RIS
TY - JOUR
T1 - Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL
AU - Husby, Simon
AU - Bæch-Laursen, Cecilie
AU - Eskelund, Christian W.
AU - Favero, Francesco
AU - Jespersen, Jakob Schmidt
AU - Hutchings, Martin
AU - Pedersen, Lone Bredo
AU - Niemann, Carsten U.
AU - Weischenfeldt, Joachim
AU - Räty, Riikka
AU - Larsen, Thomas Stauffer
AU - Kolstad, Arne
AU - Jerkeman, Mats
AU - Grønbæk, Kirsten
N1 - Funding Information:
The research was supported by Rigshospitalets Research Foundation and the Novo Nordisk Foundation (Novo Nordisk Foundation Center for Stem Cell Biology, DanStem; grant NNF17CC0027852). The project is part of the Danish Research Center for Precision Medicine in Blood Cancers funded by the Danish Cancer Society grant no. R223-A13071 and Greater Copenhagen Health Science Partners. The clinical trial was investigator-initiated and supported by Janssen and Celgene.
PY - 2022
Y1 - 2022
U2 - 10.1038/s41375-022-01725-8
DO - 10.1038/s41375-022-01725-8
M3 - Journal article
C2 - 36274067
AN - SCOPUS:85140313538
VL - 36
SP - 2912
EP - 2916
JO - Leukemia
JF - Leukemia
SN - 0887-6924
ER -
